Cogent Biosciences, Inc. (NASDAQ: COGT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
31.50
-1.69-5.09%
News
Down 5.1% — Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target (Benzinga).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -3.04 | Insider Own | - | Shs Outstand | 170.87M | Perf Week | -5.72% |
| Market Cap | 5.38B | Forward P/E | - | EPS next Y | -1.03 | Insider Trans | -7.69% | Shs Float | 148.52M | Perf Month | -14.52% |
| Enterprise Value | 4.83B | PEG | - | EPS next Q | -0.57 | Inst Own | - | Short Float | 12.62% | Perf Quarter | -8.80% |
| Income | -23.00M | P/S | - | EPS this Y | 27.16% | Inst Trans | - | Short Ratio | 7.87 | Perf Half Y | -8.99% |
| Sales | 24.00M | P/B | 10.12 | EPS next Y | 53.53% | ROA | -45.20% | Short Interest | 18.75M | Perf YTD | -11.32% |
| Book/sh | 3.11 | P/C | 6.80 | EPS next 5Y | - | ROE | -72.57% | 52W High | 43.73 -27.97% | Perf Year | 154.85% |
| Cash/sh | 4.64 | P/FCF | - | EPS past 3/5Y | - | ROIC | -50.09% | 52W Low | 11.60 171.55% | Perf 3Y | 173.91% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 3.52% 3.72% | Perf 5Y | 274.11% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | -31.03% | Oper. Margin | 0.00% | ATR (14) | 1.44 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.57 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 30.16 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.57 | EPS Q/Q | 1.89% | SMA20 | -9.03% | Beta | 0.32 | Target Price | 51.75 |
| Payout | 0.00% | Debt/Eq | 0.40 | Sales Q/Q | - | SMA50 | -15.87% | Rel Volume | 2.04 | Prev Close | 33.19 |
| Employees | 258 | LT Debt/Eq | 0.39 | Earnings | Nov 06 | SMA200 | -14.32% | Avg Volume | 2.25M | Price | 31.50 |
| IPO Date | Mar 29, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.30% - | Net Debt/EBITDA | -0.17 | Volume | 4,603,050 | Change | -5.09% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-17-26 | Reiterated | Piper Sandler | Overweight | $52 → $55 |
| Aug-12-26 | Reiterated | Guggenheim | Buy | $20 → $52 |
| Jun-01-26 | Reiterated | Stifel Nicolaus | $40 → $45 | |
| May-06-26 | Reiterated | HC Wainwright & Co. | Buy | $52 → $55 |
| Feb-19-26 | Reiterated | Robert W. Baird | $34 → $35 | |
| Feb-18-26 | Reiterated | Piper Sandler | Overweight | $52 |
| Jan-07-26 | Reiterated | UBS | $60 | |
| Jan-06-26 | Reiterated | HC Wainwright & Co. | Buy | $14 → $52 |
| Dec-08-25 | Reiterated | Jefferies | Buy | $45 → $48 |
| Nov-11-25 | Reiterated | Raymond James | $30 → $60 |
Latest News· Times ET
Sep-16-26
Sep-16-2604:22AM
Sep-15-26
Sep-15-2604:00AM
Sep-02-26
Aug-31-26
Aug-31-2602:30PM
Aug-27-26
Aug-24-26
Aug-24-2612:18AM
Aug-23-26
Aug-17-26
Aug-17-2611:38PM
Aug-13-26
Aug-13-2606:56AM
Aug-10-26
Aug-10-2601:27PM
04:00AM
Jul-28-26
Jul-28-2606:00AM
Jul-18-26
Jul-18-2611:10PM
Jun-30-26
Company
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 24 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 34 | 5 | 0 | — | — | — | — | — | — | |
| Gross Profit | -11 | -5 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 13 | 64 | 43 | — | — | — | — | — | — | |
| Research and Development | 34 | 270 | 233 | — | — | — | — | — | — | |
| Other Operating Expense | -24 | -5 | 0 | — | — | — | — | — | — | |
| Operating Income | -23 | -333 | -276 | — | — | — | — | — | — | |
| Interest Expense | 0 | 3 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 7 | 20 | — | — | — | — | — | — | |
| Net Income Before Taxes | -23 | -329 | -256 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -23 | -329 | -256 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -23 | -329 | -256 | — | — | — | — | — | — | |
| Net Income | -23 | -329 | -256 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.04 | -2.04 | -2.32 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.04 | -2.04 | -2.32 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.04 | -2.04 | -2.32 | — | — | — | — | — | — | |
| EBITDA | -22 | -321 | -252 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 10.50 | — | — | — | — | — | — | — | — | |
| Gross Margin | -45.83 | — | — | — | — | — | — | — | — | |
| Operating Margin | -95.83 | — | — | — | — | — | — | — | — | |
| Net Margin | -95.83 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 8 | 161 | 110 | — | — | — | — | — | — | |
| Market Capitalization | 252 | 5,719 | 858 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Morris Arlene | Director | Aug 27 '26 | Sale | 37.12 | 45,510 | 1,689,493 | 0 | Aug 31 |
| Morris Arlene | Director | Aug 27 '26 | Option Exercise | 5.39 | 45,510 | 245,497 | 45,510 | Aug 31 |
| Fairmount Funds Management LLC | Director | Mar 31 '26 | Sale | 34.66 | 7,000,000 | 242,620,000 | 5,503,418 | Mar 31 |
| Fairmount Funds Management LLC | Director | Jan 22 '26 | Sale | 36.40 | 3,500,000 | 127,400,000 | 5,503,418 | Jan 22 |
| Kearns Evan | Chief Legal Officer | Dec 26 '25 | Sale | 38.70 | 65,000 | 2,515,500 | 109,398 | Dec 30 |
| Green John L. | Chief Financial Officer | Dec 26 '25 | Sale | 38.68 | 77,000 | 2,978,360 | 131,834 | Dec 30 |
| Sachs Jessica | Chief Medical Officer | Dec 26 '25 | Sale | 38.70 | 82,642 | 3,198,245 | 133,938 | Dec 30 |
| Robinson John Edward | Chief Scientific Officer | Dec 26 '25 | Sale | 38.74 | 90,000 | 3,486,600 | 140,002 | Dec 30 |
| Fairmount Funds Management LLC | Director | Jul 10 '25 | Buy | 9.00 | 2,777,777 | 24,999,993 | 9,003,418 | Jul 14 |
| Pinnow Cole | Chief Commercial Officer | Jan 14 '25 | Buy | 7.60 | 43,750 | 332,413 | 45,848 | Jan 15 |
| Fairmount Funds Management LLC | Director | Jun 10 '24 | Option Exercise | 0.00 | 1,501,500 | 1,500 | 6,225,641 | Jun 12 |
| Fairmount Funds Management LLC | 10% Owner | Jun 09 '23 | Buy | 12.00 | 800,000 | 9,600,000 | 3,272,124 | Jun 13 |
| Fairmount Funds Management LLC | director: | Jun 16 '22 | Buy | 8.25 | 1,200,000 | 9,900,000 | 2,472,124 | Jun 21 |
| Green John L. | Chief Financial Officer | Apr 26 '21 | Sale | 8.86 | 35,626 | 315,646 | 3,841 | Apr 28 |
| CAMPANA DARIO | 10% Owner | May 12 '20 | Sale | 0.46 | 98,200 | 45,545 | 3,095,114 | Oct 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.